20 June 2013
Keywords: ono, licenses, progenics, oic, drug, japan, japanese
Article | 27 October 2008
Japanese drugmaker Ono has acquired the local rights to Progenics' Relistor (methylnaltrexone bromide), and it plans to develop and
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
27 October 2008
19 June 2013
© 2013 thepharmaletter.com